Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Goodwill & Intangibles: 2018-2024

Historic Goodwill & Intangibles for Akebia Therapeutics (AKBA) over the last 7 years, with Dec 2024 value amounting to $59.0 million.

  • Akebia Therapeutics' Goodwill & Intangibles fell 13.24% to $59.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.0 million, marking a year-over-year decrease of 13.24%. This contributed to the annual value of $59.0 million for FY2024, which is 37.90% down from last year.
  • Akebia Therapeutics' Goodwill & Intangibles amounted to $59.0 million in FY2024, which was down 37.90% from $95.1 million recorded in FY2023.
  • Akebia Therapeutics' 5-year Goodwill & Intangibles high stood at $199.3 million for FY2020, and its period low was $59.0 million during FY2024.
  • Moreover, its 3-year median value for Goodwill & Intangibles was $95.1 million (2023), whereas its average is $95.1 million.
  • Per our database at Business Quant, Akebia Therapeutics' Goodwill & Intangibles tumbled by 42.46% in 2020 and then increased by 16.11% in 2021.
  • MRY analysis of 5 years shows Akebia Therapeutics' Goodwill & Intangibles stood at $199.3 million in 2020, then dropped by 16.11% to $167.2 million in 2021, then decreased by 21.56% to $131.1 million in 2022, then dropped by 27.49% to $95.1 million in 2023, then tumbled by 37.90% to $59.0 million in 2024.
  • Its last three reported values are $59.0 million in FY2024, $95.1 million for FY2023, and $131.1 million during FY2022.